Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2023-08-31
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Using the pretreatment nutrition status and quality of life as predictors to sorafenib response
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
NCT01932385
Residual Plasma Concentration of Sorafenib and Adverse Events in CHC
NCT03340636
Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma
NCT02834546
Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
NCT00844688
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
NCT00976170
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
age sex body weight and height (BMI) pre-therapy laboratory counts of white cells, neutrophils, lymphocytes, monocyte, hemoglobin and platelets; bilirubin, albumin and globulin concentration, AST, ALT, AFP, PT and CONC
Barcelona Clinic Liver Cancer Stage (BCLC) of all patients
The neutrophil-to- lymphocyte ratio (NLR) was calculated by dividing the neutrophil count by the lymphocyte count.
The platelet- to-lymphocyte ratio (PLR) was calculated by dividing the platelet count by the lymphocyte count.
Weight loss difference after treatment Portal hypertension was defined as presence of either collaterals on radiological examination, esophageal varices by upper gastrointestinal endoscopy and/or thrombocytopenia.
Quality of life assessment. QoL was assessed using FACT Hepatobiliary Symptom Index (FHSI-8) Questionnaire. QoL was assessed at base line and 3-6 months after start of treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hepatocellular carcinoma receiving sorafenib
Patient with advanced stage HCC receiving sorafenib
The neutrophil-to- lymphocyte ratio
It was calculated by dividing the neutrophil count by the lymphocyte count.
Prognostic nutrition index
It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The neutrophil-to- lymphocyte ratio
It was calculated by dividing the neutrophil count by the lymphocyte count.
Prognostic nutrition index
It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients recieving other treatment modalities
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mona Mohammed Abdelrhman
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amr Zagloul, MD
Role: STUDY_DIRECTOR
Sohag University
Ahmed othman, MD
Role: STUDY_CHAIR
Sohag University
Rafat Abd El Aal, MD
Role: STUDY_CHAIR
Sohag University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Takagi K, Buettner S, Ijzermans JNM. Prognostic significance of the controlling nutritional status (CONUT) score in patients with colorectal cancer: A systematic review and meta-analysis. Int J Surg. 2020 Jun;78:91-96. doi: 10.1016/j.ijsu.2020.04.046. Epub 2020 Apr 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-23-07-07PD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.